Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

istrative expenses is primarily due to cost savings related to recent restructurings.

The Company's balance sheet on September 30, 2008 reflected total assets of $207.7 million, including cash and investments of $118.2 million compared with balances at December 31, 2007 of $276.7 million and $179.4 million, respectively. The Company expects to end 2008 with approximately $100 million in cash and investments.

"We are pleased with the progress of our GnRH program, especially the recent positive results of our 603 study where once a day elagolix showed profound efficacy with minimal impact on bone mineral density. We are also nearing completion of the final preclinical studies of urocortin 2 to allow for long-term Phase II clinical studies and our scientists have just recently identified a clinical candidate from our VMAT2 development program for movement disorders," said Kevin Gorman, Chief Executive Officer and President of Neurocrine Biosciences. "While we are making great strides in advancing our pipeline, we continue to prioritize expenditures and diligently manage our cash burn."

R & D Pipeline Update

Neurocrine's clinical development group and corporate partners have five programs in clinical development. Neurocrine scientists continue to supply Neurocrine's pipeline to meet the Company-wide goal of bringing one new compound into development each year.

Elagolix for Endometriosis

The Company recently announced the positive safety and efficacy results from the completed 6-month treatment phase of its Phase IIb clinical trial (PETAL Study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix.

The primary endpoint, percent change from baseline in mean bone mineral density (BMD) demonstrated elagolix did not induce significant bone loss over the six month treatment period. Additionally, elagolix also met the secondary endpoints of improvement in endometrios
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Custom Computer Specialists, ... today that they are silver sponsors of the Primary ... PCDC sponsor, Custom is lending their support of PCDC,s ... communities. Since its founding in 1993, PCDC ... primary care area.  PCDC has financed over 100 completed ...
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter ... — a revolutionary new archwire that allows orthodontists to simultaneously apply different forces ... the efficacy of SmartArch. “We’re thrilled about taking SmartArch one step closer to ...
(Date:6/29/2015)... and Manhattan, KS (PRWEB) , ... June 29, ... ... acquired US PATENT 7736892 B2. Under the terms of the agreement, MediVet will ... Cord Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as a ...
(Date:6/29/2015)... June 29, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... "Pete" Petit, has been awarded the Lifetime Achievement Award ... Program. The Entrepreneur Of The Year ...
Breaking Biology Technology:Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2
... ... ,For Excellence In The International Marketplace. , ... (PRWEB) March 24, 2010 -- Sterlitech Corporation, one of the ... acceptance of the prestigious Faces of Trade® Award presented by the US Chamber of ...
... , ... , ... ... NEW YORK , March 23 The Michael J. Fox Foundation announced that monoclonal ...
... Qteros, Inc., and the University of Massachusetts Amherst announced today that the ... Producing Biofuels and Related Materials" describing the novel creation of products, including biofuels, through the fermentation ... ... ...
Cached Biology Technology:US Chamber Of Commerce Honors Sterlitech Corporation 2Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development 2Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development 3Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development 4Qteros and UMass Amherst Announce the Issuance of a U.S. Patent for Production of Ethanol From a Unique Microorganism, the Q Microbe(TM) 2Qteros and UMass Amherst Announce the Issuance of a U.S. Patent for Production of Ethanol From a Unique Microorganism, the Q Microbe(TM) 3Qteros and UMass Amherst Announce the Issuance of a U.S. Patent for Production of Ethanol From a Unique Microorganism, the Q Microbe(TM) 4Qteros and UMass Amherst Announce the Issuance of a U.S. Patent for Production of Ethanol From a Unique Microorganism, the Q Microbe(TM) 5Qteros and UMass Amherst Announce the Issuance of a U.S. Patent for Production of Ethanol From a Unique Microorganism, the Q Microbe(TM) 6
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
(Date:6/18/2015)... NEW YORK , June 18, 2015 ... in US$ Million by the following Product Segments, which ... Immunoassay Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and ... for the US, Canada , ... Asia-Pacific , Latin America ...
(Date:6/17/2015)... Fla. , June 17, 2015  Crossmatch™, ... today announced that its U.are.U ® 4500 ... Togo,s Eateries, Inc., a ... sandwich chain, to increase security, improve accountability and ... readers enable instant, non-repudiable identity confirmation for employee ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... New research shows that following a vegetarian diet and ... risk of diabetes in African Americans, who are twice as ... whites. "These findings are encouraging for preventing ... susceptible to the disease than other populations," said Serena Tonstad, ...
... York, November 3, 2011 Impulsive individuals tend ... drug and alcohol abuse, to problem gambling and difficult ... social situations. Impulsivity is also a common feature of ... shows that people may react this way, in part, ...
... which people use before progressing to the use of ... this progression is called the "gateway sequence" of drug ... by Amir Levine, MD, Denise Kandel, PhD; Eric Kandel, ... the first molecular explanation for the gateway sequence. They ...
Cached Biology News:Vegetarian diet, physical activity protect against diabetes in black population, study shows 2Impulsive versus controlled men: Disinhibited brains and disinhibited behavior 2Nicotine primes brain for cocaine use: Molecular basis of gateway sequence of drug use 2
... raised against a partial recombinant ... PPP4C (NP_002711, 218 a.a. ... protein with GST tag. ... NM_002720 Protein ...
Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
...
... array sample elements. , , ,Includes:, , , ... PBS (10X): 50 ml , INDIA HisProbe HRP: 0.2 ... 10% Tween-20: 2 x 10 ml ampules , SuperSignal ... SuperSignal West Pico Stable Peroxide: 2 x 25 ...
Biology Products: